美敦力第二财季业绩超预期，心血管业务销售额同比增长超一成

Core Insights - Medtronic reported Q2 FY2026 net sales of $8.96 billion, exceeding analyst expectations of $8.87 billion [1] - Adjusted earnings per share were $1.36, higher than the anticipated $1.31 [1] - The cardiovascular segment saw a year-over-year sales increase of 10.8%, reaching $3.44 billion [1] Financial Performance - Q2 FY2026 net sales: $8.96 billion, above expectations [1] - Adjusted EPS: $1.36, surpassing forecasts [1] - Cardiovascular sales: $3.44 billion, up 10.8% year-over-year [1] Future Outlook - The company raised the lower end of its adjusted EPS guidance for FY2026 from $5.60 to $5.62, while maintaining the upper end at $5.66 [1] - Organic revenue growth forecast for the full year increased from approximately 5% to about 5.5% [1]